Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study
PURPOSEOur investigation assessed the impact of geographical disparities in the treatment of patients with advanced urothelial cancer (aUC) included in the international, real-world ARON-2 trial.PATIENTS AND METHODSThe study population comprised 1,137 patients with aUC treated with pembrolizumab for...
Saved in:
| Main Authors: | Mimma Rizzo, Andrey Soares, Shilpa Gupta, Fabio Calabrò, Hideki Takeshita, Maria Teresa Bourlon, Se Hoon Park, Patrizia Giannatempo, Zin War Myint, Thomas Büttner, Enrique Grande, Ondrej Fiala, Daniele Santini, Aristotelis Bamias, Roubini Zakopoulou, Sebastiano Buti, Ravindran Kanesvaran, Pasquale Rescigno, Javier Molina-Cerrillo, Ilana Epstein, Fernando Sabino Marques Monteiro, Francesco Massari, Camillo Porta, Joaquin Bellmunt, Matteo Santoni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-07-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
by: Camillo Porta, et al.
Published: (2025-05-01) -
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
by: Mimma Rizzo, et al.
Published: (2025-02-01) -
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
by: Matteo Santoni, et al.
Published: (2025-05-01) -
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
by: Maria T. Bourlon, et al.
Published: (2025-07-01) -
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
by: Giandomenico Roviello, et al.
Published: (2025-01-01)